Skip Navigation



JAC Advance Access published online on March 16, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki085
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/721    most recent
dki085v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wang, E.
Right arrow Articles by Bergeron, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, E.
Right arrow Articles by Bergeron, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Received October 8, 2004
Revised January 24, 2005
Accepted February 2, 2005

Original article

Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia

Erjian Wang 1, Yves Bergeron 1, and Michel G. Bergeron 1*

1 Research Center for Infectious Diseases, Laval University, Quebec City, Quebec, Canada G1V 4G2

* To whom correspondence should be addressed.
Michel G. Bergeron, E-mail: Michel.G.Bergeron{at}crchul.ulaval.ca


  Abstract

Objectives: Anti-inflammatory therapy with interleukin-10 (IL-10) was previously reported to reduce pulmonary inflammation and to prevent septicaemia in murine pneumococcal pneumonia treated with ceftriaxone. In the present report, we investigated the influence of pulmonary infection and IL-10 administration on the pharmacokinetics of ceftriaxone.

Methods: CD1 mice were infected with 107 cfu of Streptococcus pneumoniae. Treatments (intraperitoneal) with IL-10 (1 µg per mouse), ceftriaxone (20 mg/kg) or the combination of IL-10 + ceftriaxone were initiated 18 h after infection. Groups of mice were sacrificed at several time points from 5 min to 24 h after initiation of therapy. Ceftriaxone was quantified in blood and lungs using a microbiological assay. Additional groups of mice received a second dose of IL-10 at 36 h post-infection. Survival rates were recorded over 14 days.

Results: The clearance of ceftriaxone was significantly reduced in infected mice compared with that in non-infected animals (P < 0.01), whereas AUC, mean residence time, t1/2 and AUClung/AUCserum were significantly enhanced (P < 0.01, 0.01, 0.05, 0.05). Co-administration of IL-10 with ceftriaxone in infected animals further retained ceftriaxone in the bloodstream and reduced its volume of distribution at steady state and the ratio of AUClung/AUCserum. IL-10 alone did not modify significantly the pharmacokinetics of ceftriaxone in blood and lungs of non-infected animals.

Conclusions: The results suggest that pulmonary infection, and therapy with IL-10, both affect the pharmacokinetics of ceftriaxone. Indeed, administration of IL-10 + ceftriaxone improved the survival rate of mice (P < 0.001 compared with therapy with ceftriaxone alone). IL-10 should be considered as an adjunctive therapy to antibiotics against severe infections.

Keywords: Streptococcus pneumoniae; IL-10; inflammation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. L. Crandon, A. Kim, and D. P. Nicolau
Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs
J. Antimicrob. Chemother., October 1, 2009; 64(4): 837 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Chiavolini, G. Pozzi, and S. Ricci
Animal Models of Streptococcus pneumoniae Disease
Clin. Microbiol. Rev., October 1, 2008; 21(4): 666 - 685.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. P. Mizgerd
Acute Lower Respiratory Tract Infection
N. Engl. J. Med., February 14, 2008; 358(7): 716 - 727.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.